Professional Bio
Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.
Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.
Patient Care Bio
Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.
Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.
